Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Stoeckle

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Open Forum Infectious Diseases|December 14, 2019
Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced PatientsFlaminia Olearo, Huyen Nguyen, Fabrice Bonnet, et al.
BMJ Open|November 13, 2020
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trialMikaela Smit, Annalisa Marinosci, Giovanni Jacopo Nicoletti, et al.
Open Forum Infectious Diseases|October 30, 2019
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced PatientsFlaminia Olearo, Huyen Nguyen, Fabrice Bonnet, et al.
Open Forum Infectious Diseases|September 23, 2022
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency VirusBernadette Jakeman, Alexandra U Scherrer, Katharine E A Darling, et al.
Plos One|March 2, 2021
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in SwitzerlandKatharine E A Darling, Isabella Locatelli, Nadia Benghalem, et al.
Pharmaceutics|August 26, 2022
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in SwitzerlandPaul Thoueille, Susana Alves Saldanha, Fabian Schaller, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2023
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1Suraj Balakrishna, Tom Loosli, Maryam Zaheri, et al.
Swiss Medical Weekly|August 10, 2021
Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort studyMihaela Sava, Gregor Sommer, Thomas Daikeler, et al.
International Journal of Epidemiology|August 7, 2021
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)Alexandra U Scherrer, Anna Traytel, Dominique L Braun, et al.
Swiss Medical Weekly|June 27, 2022
Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort studyBabette L Winter, Frédérique Hovaguimian, Roger D Kouyos, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Open Forum Infectious Diseases|December 14, 2019
Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced PatientsFlaminia Olearo, Huyen Nguyen, Fabrice Bonnet, et al.
BMJ Open|November 13, 2020
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trialMikaela Smit, Annalisa Marinosci, Giovanni Jacopo Nicoletti, et al.
Open Forum Infectious Diseases|October 30, 2019
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced PatientsFlaminia Olearo, Huyen Nguyen, Fabrice Bonnet, et al.
Open Forum Infectious Diseases|September 23, 2022
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency VirusBernadette Jakeman, Alexandra U Scherrer, Katharine E A Darling, et al.
Plos One|March 2, 2021
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in SwitzerlandKatharine E A Darling, Isabella Locatelli, Nadia Benghalem, et al.
Pharmaceutics|August 26, 2022
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in SwitzerlandPaul Thoueille, Susana Alves Saldanha, Fabian Schaller, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2023
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1Suraj Balakrishna, Tom Loosli, Maryam Zaheri, et al.
Swiss Medical Weekly|August 10, 2021
Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort studyMihaela Sava, Gregor Sommer, Thomas Daikeler, et al.
International Journal of Epidemiology|August 7, 2021
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)Alexandra U Scherrer, Anna Traytel, Dominique L Braun, et al.
Swiss Medical Weekly|June 27, 2022
Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort studyBabette L Winter, Frédérique Hovaguimian, Roger D Kouyos, et al.
Pageof 8